Publication | Closed Access

Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study

Interim AnalysisFood IntoleranceBolus ExposureAllergyAutoimmune DiseaseCoeliac DiseaseImmunodeficienciesImmunologyGastroenterologyClinical PresentationAutoimmunityCeliac DiseaseMedicine